866-997-4948(US-Canada Toll Free)

Urinary Tract Infections - Pipeline Review, H1 2014

Published By :

Global Markets Direct

Published Date : Mar 2014

Category :

Diseases & Conditions

No. of Pages : 114 Pages


This report provides comprehensive information on the therapeutic development for Urinary Tract Infections, complete with comparative analysis at various stages, therapeutics assessment by drug target, mechanism of action (MoA), route of administration (RoA) and molecule type, along with latest updates, and featured news and press releases. It also reviews key players involved in the therapeutic development for Urinary Tract Infections and special features on late-stage and discontinued projects.

Global Markets Directs report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Directs proprietary databases, Company/University websites, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources, put together by Global Markets Directs team. Drug profiles/records featured in the report undergoes periodic updation following a stringent set of processes that ensures that all the profiles are updated with the latest set of information. Additionally, processes including live news & deals tracking, browser based alert-box and clinical trials registries tracking ensure that the most recent developments are captured on a real time basis.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage. It strengthens R&D pipelines by identifying new targets and MOAs to produce first-in-class and best-in-class products.

Scope

  • The report provides a snapshot of the global therapeutic landscape of Urinary Tract Infections
  • The report reviews key pipeline products under drug profile section which includes, product description, MoA and R&D brief, licensing and collaboration details & other developmental activities 
  • The report reviews key players involved in the therapeutics development for Urinary Tract Infections and enlists all their major and minor projects
  • The report summarizes all the dormant and discontinued pipeline projects 
  • A review of the Urinary Tract Infections products under development by companies and universities/research institutes based on information derived from company and industry-specific sources
  • Pipeline products coverage based on various stages of development ranging from pre-registration till discovery and undisclosed stages
  • A detailed assessment of monotherapy and combination therapy pipeline projects
  • Coverage of the Urinary Tract Infections pipeline on the basis of target, MoA, route of administration and molecule type
  • Latest news and deals relating related to pipeline products

Reasons to buy

  • Provides strategically significant competitor information, analysis, and insights to formulate effective R&D development strategies
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop strategic initiatives by understanding the focus areas of leading companies
  • Identify and understand important and diverse types of therapeutics under development for Urinary Tract Infections
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Devise corrective measures for pipeline projects by understanding Urinary Tract Infections pipeline depth and focus of Indication therapeutics
  • Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope
  • Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents

Table of Contents 2

List of Tables 6
List of Figures 6
Introduction 8
Global Markets Direct Report Coverage 8
Urinary Tract Infections Overview 9
Therapeutics Development 10
Pipeline Products for Urinary Tract Infections Overview 10
Pipeline Products for Urinary Tract Infections Comparative Analysis 11
Urinary Tract Infections Therapeutics under Development by Companies 12
Urinary Tract Infections Therapeutics under Investigation by Universities/Institutes 15
Urinary Tract Infections Pipeline Products Glance 16
Late Stage Products 16
sClinical Stage Products 16
Clinical Stage Products 17
Early Stage Products 18
Urinary Tract Infections Products under Development by Companies 19
Urinary Tract Infections Products under Investigation by Universities/Institutes 20
Urinary Tract Infections Companies Involved in Therapeutics Development 21
Shionogi & Co., Ltd. 21
AstraZeneca PLC 22
Merck & Co., Inc. 23
Melinta Therapeutics, Inc 24
Cubist Pharmaceuticals, Inc. 25
Nippon Shinyaku Co., Ltd. 26
Paratek Pharmaceuticals, Inc. 27
Nymox Pharmaceutical Corporation 28
CytoTools AG 29
Achaogen Inc. 30
MerLion Pharmaceuticals Pte Ltd 31
Osel Inc. 32
FOB Synthesis, Inc. 33
Sequoia Sciences, Inc. 34
Tetraphase Pharmaceuticals Inc. 35
Da Volterra 36
Biota Pharmaceuticals, Inc. 37
Adenium Biotech ApS 38
Urinary Tract Infections Therapeutics Assessment 39
Assessment by Monotherapy Products 39
Assessment by Combination Products 40
Assessment by Target 41
Assessment by Mechanism of Action 44
Assessment by Route of Administration 47
Assessment by Molecule Type 49
Drug Profiles 51
prulifloxacin - Drug Profile 51
Product Description 51
Mechanism of Action 51
R&D Progress 51
(ceftolozane + tazobactam) - Drug Profile 53
Product Description 53
Mechanism of Action 53
R&D Progress 53
eravacycline - Drug Profile 55
Product Description 55
Mechanism of Action 55
R&D Progress 55
(ceftazidime + avibactam) - Drug Profile 57
Product Description 57
Mechanism of Action 57
R&D Progress 57
dexamethasone acetate - Drug Profile 59
Product Description 59
Mechanism of Action 59
R&D Progress 59
plazomicin - Drug Profile 60
Product Description 60
Mechanism of Action 60
R&D Progress 60
delafloxacin - Drug Profile 62
Product Description 62
Mechanism of Action 62
R&D Progress 62
LACTIN-V - Drug Profile 65
Product Description 65
Mechanism of Action 65
R&D Progress 65
(ceftaroline + avibactam) - Drug Profile 66
Product Description 66
Mechanism of Action 66
R&D Progress 66
UtiSept - Drug Profile 68
Product Description 68
Mechanism of Action 68
R&D Progress 68
finafloxacin - Drug Profile 69
Product Description 69
Mechanism of Action 69
R&D Progress 69
MK-7655 - Drug Profile 71
Product Description 71
Mechanism of Action 71
R&D Progress 71
omadacycline tosylate - Drug Profile 73
Product Description 73
Mechanism of Action 73
R&D Progress 73
S-649266 - Drug Profile 76
Product Description 76
Mechanism of Action 76
R&D Progress 76
Vaccine Program - Drug Profile 77
Product Description 77
Mechanism of Action 77
R&D Progress 77
NXB-4221 - Drug Profile 79
Product Description 79
Mechanism of Action 79
R&D Progress 79
MAR Program - Drug Profile 80
Product Description 80
Mechanism of Action 80
R&D Progress 80
GP-4 - Drug Profile 81
Product Description 81
Mechanism of Action 81
R&D Progress 81
Micselon - Drug Profile 82
Product Description 82
Mechanism of Action 82
R&D Progress 82
cefepime - Drug Profile 83
Product Description 83
Mechanism of Action 83
R&D Progress 83
Nu-3 - Drug Profile 84
Product Description 84
Mechanism of Action 84
R&D Progress 84
DAV-210 - Drug Profile 85
Product Description 85
Mechanism of Action 85
R&D Progress 85
GyrB/ParE Antibiotic - Drug Profile 86
Product Description 86
Mechanism of Action 86
R&D Progress 86
AA-139 - Drug Profile 87
Product Description 87
Mechanism of Action 87
R&D Progress 87
FSI-1686 - Drug Profile 88
Product Description 88
Mechanism of Action 88
R&D Progress 88
NXC-4720 - Drug Profile 89
Product Description 89
Mechanism of Action 89
R&D Progress 89
Urinary Tract Infections Recent Pipeline Updates 90
Urinary Tract Infections Dormant Projects 104
Urinary Tract Infections Discontinued Products 105
Urinary Tract Infections Product Development Milestones 106
Featured News & Press Releases 106
Oct 02, 2013: Cubist To Present Data On Late Stage Candidates Ceftolozane/Tazobactam At IDWeek 2013 106
Sep 30, 2013: Tetraphase Outlines Plans for Phase 3 Clinical Trial of Eravacycline IV/oral in Complicated Urinary Tract Infections 107
Jul 15, 2013: FDA Grants QIDP Designation to Eravacycline, Tetraphase\'s Lead Antibiotic Product Candidate 108
May 07, 2013: Cubists Late-stage Antibiotic Candidate CXA-201 Receives FDA Fast Track Designation 108
Jan 07, 2013: Cubist Pharma Provides Update On Infectious Disease Drug Candidate, Ceftolozane 108
Dec 11, 2012: MerLion Pharma Initiates First Phase II Clinical Study With Finafloxacin In Patients With Complicated Urinary Tract Infections 109
Dec 06, 2012: Cubist Pharma\'s Antibiotic Candidate Ceftolozane Obtains QIDP Designation From FDA 110
Nov 07, 2012: MerLion Pharma Successfully Completes Phase I Clinical Study With Intravenously Administered Finafloxacin 110
Oct 05, 2012: Anacor Pharma\'s Collaboration Partner GlaxoSmithKline Discontinues Clinical Development Of GSK2251052 111
Sep 12, 2012: Merck Announces Presentation Of Scientific Data On Investigational Agent MK-7655 At 52nd Annual ICAAC 111

Appendix 113
Methodology 113
Coverage 113
Secondary Research 113
Primary Research 113
Expert Panel Validation 113
Contact Us 114
Disclaimer 114

List of Table


Number of Products under Development for Urinary Tract Infections, H1 2014 10
Number of Products under Development for Urinary Tract Infections Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 13
Number of Products under Development by Companies, H1 2014 (Contd..1) 14
Number of Products under Investigation by Universities/Institutes, H1 2014 15
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Development, H1 2014 18
Products under Development by Companies, H1 2014 19
Products under Investigation by Universities/Institutes, H1 2014 20
Urinary Tract Infections Pipeline by Shionogi & Co., Ltd., H1 2014 21
Urinary Tract Infections Pipeline by AstraZeneca PLC, H1 2014 22
Urinary Tract Infections Pipeline by Merck & Co., Inc., H1 2014 23
Urinary Tract Infections Pipeline by Melinta Therapeutics, Inc, H1 2014 24
Urinary Tract Infections Pipeline by Cubist Pharmaceuticals, Inc., H1 2014 25
Urinary Tract Infections Pipeline by Nippon Shinyaku Co., Ltd., H1 2014 26
Urinary Tract Infections Pipeline by Paratek Pharmaceuticals, Inc., H1 2014 27
Urinary Tract Infections Pipeline by Nymox Pharmaceutical Corporation, H1 2014 28
Urinary Tract Infections Pipeline by CytoTools AG, H1 2014 29
Urinary Tract Infections Pipeline by Achaogen Inc., H1 2014 30
Urinary Tract Infections Pipeline by MerLion Pharmaceuticals Pte Ltd, H1 2014 31
Urinary Tract Infections Pipeline by Osel Inc., H1 2014 32
Urinary Tract Infections Pipeline by FOB Synthesis, Inc., H1 2014 33
Urinary Tract Infections Pipeline by Sequoia Sciences, Inc., H1 2014 34
Urinary Tract Infections Pipeline by Tetraphase Pharmaceuticals Inc., H1 2014 35
Urinary Tract Infections Pipeline by Da Volterra, H1 2014 36
Urinary Tract Infections Pipeline by Biota Pharmaceuticals, Inc., H1 2014 37
Urinary Tract Infections Pipeline by Adenium Biotech ApS, H1 2014 38
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Stage and Target, H1 2014 43
Number of Products by Stage and Mechanism of Action, H1 2014 46
Number of Products by Stage and Route of Administration, H1 2014 48
Number of Products by Stage and Molecule Type, H1 2014 50
Urinary Tract Infections Therapeutics Recent Pipeline Updates, H1 2014 90
Urinary Tract Infections Dormant Projects, H1 2014 104
Urinary Tract Infections Discontinued Products, H1 2014 105

List of Chart


Number of Products under Development for Urinary Tract Infections, H1 2014 10
Number of Products under Development for Urinary Tract Infections Comparative Analysis, H1 2014 11
Number of Products under Development by Companies, H1 2014 12
Comparative Analysis by Late Stage Development, H1 2014 16
Comparative Analysis by Clinical Stage Development, H1 2014 17
Comparative Analysis by Early Stage Products, H1 2014 18
Assessment by Monotherapy Products, H1 2014 39
Assessment by Combination Products, H1 2014 40
Number of Products by Top 10 Target, H1 2014 41
Number of Products by Stage and Top 10 Target, H1 2014 42
Number of Products by Top 10 Mechanism of Action, H1 2014 44
Number of Products by Stage and Top 10 Mechanism of Action, H1 2014 45
Number of Products by Top 10 Route of Administration, H1 2014 47
Number of Products by Stage and Top 10 Route of Administration, H1 2014 48
Number of Products by Top 10 Molecule Type, H1 2014 49
Number of Products by Stage and Top 10 Molecule Type, H1 2014 50

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title *
  • Company *
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *